Sweden · Delayed Price · Currency is SEK Bactiguard Holding AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 delivered continued EBITDA profitability despite a 16% revenue decline, mainly due to lower BD shipments and timing effects. Strategic partnerships advanced, with BD launching coated Foley catheters in Europe and Zimmer Biomet transitioning to a new business setup.
Fiscal Year 2025
-
Q4 saw strong EBITDA growth and improved profitability, driven by an updated Zimmer Biomet agreement and cost reductions, despite lower full-year revenues from currency effects and discontinued business. Strategic partnerships expanded, and new therapeutic areas showed early promise.
-
Q3 2025 saw positive EBITDA of SEK 5.3 million despite a 35% revenue decline, driven by currency headwinds and lower license and wound management sales. Partnerships with BD and Zimmer Biomet showed in-market growth and clinical progress, while cost reductions improved margins.
-
A strategic shift to a license partnership model has driven profitability and growth, with validated infection-prevention technology and major partnerships fueling expansion. Targets for 2030 include SEK 600 million in revenue, with strong momentum in wound management and new therapeutic areas.
-
Q2 2025 saw continued EBITDA profitability and improved net loss, despite a 14% revenue decline due to delayed BD market launches and currency effects. Hydrocyn Aqua drove strong wound management growth, and early feasibility work in cardiology was initiated.
-
Q1 2025 saw 7% revenue growth and continued profitability, with strong performance in wound management and licensed business segments. Updated 2030 targets were announced, and key partnerships, especially with BD, drove expansion. Cash position declined due to loan repayment.
-
New 2030 targets set: over 10 licensed application areas, SEK 600 million in revenue, and SEK 200 million EBITDA, with two-thirds of growth from existing business. Focus remains on partnerships in five key therapeutic areas and disciplined cost management.
Fiscal Year 2024
-
Revenues and EBITDA profitability increased for both Q4 and full year 2024, driven by strong license revenue growth, cost savings, and a strategic shift to a licensing-focused model. The BD partnership expanded, while the Zimmer Biomet orthopedics agreement ended, impacting future revenues.
-
Q3 saw a return to EBITDA profitability and nearly 50% revenue growth, led by strong BD partnership performance. The Zimmer Biomet contract termination impacts long-term targets, but the trauma segment partnership continues and wound management showed robust growth.
-
Q2 2024 saw 19% revenue growth year-over-year and a return to positive EBITDA, driven by stabilizing license revenues and cost reductions. Partnerships with BD and Zimmer Biomet are expanding, with future growth expected from new markets and product launches.